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Abstract
The chapter “Indomethacin from Anti-inflammatory to Anticancer Agent” covers the 
recent reports regarding the implication of COX-2/PGE2 in multiple cancer cell prolif-
eration to emphasize the anticancer potential of COX-inhibitors including indomethacin 
and to reveal that the reduction of PGE2 production interferes with the cancer cell prolif-
eration belongs to multiple cancer cell types. Impressively, indomethacin is involved in 
antiproliferative and apoptotic actions against cancer cell types via COX-2-independent 
mechanisms to highlight indomethacin as promising anticancer agent with dual actions 
to control the cancer cell proliferation. The cardiovascular complications result from dia-
ryl heterocycle sulfonamide/methylsulfone selective COX-2 inhibitors upon reduction in 
PGE2 and PGI2 production that affects the vascular tone limits the use of Celecoxib as 
chemopreventive agent against recurrence of colorectal carcinoma cells. Kinetic profile 
of indomethacin against COX-2 showed obvious difference from that of selective COX-2 
inhibitors in which it recovered completely from the enzyme after long time of incubation 
while COX-2 inhibitors did not recover to impress that this might be implicated in the 
cardiovascular toxicity of the selective inhibitors. This raised the concern to develop the 
indomethacin from nonselective COX- to selective COX-2-inhibitors and to assert whether 
the cardiac complications are from pharmacological class effect or chemical class effect.
Keywords: indomethacin, COX-2-independent mechanism, apoptosis, antiproliferative, 
kinetic profile
1. Introduction
Indomethacin is indole-3-acetic acid derivative, classified as nonsteriodal anti-inflammatory 
drug (NSAID). The drug is primarily used for the treatment of painful inflammatory conditions 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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that involves gout and osteoarthritis [1]. The mechanistic role of indomethacin in inhibition of 
pain has been verified by being nonselective inhibitor to cyclooxygenase-1 (COX-1) and cyclo-
oxygenase-2 (COX-2) isozymes [2]. The enzymatic activity of COX involves bis-oxygenation 
of arachidonic acid to (prostaglandin G2) PGG2, which then reduced to PGH2 in a peroxidase 
reaction by the same protein [3]. COX-1 is constitutively expressed in most tissues, to which 
the production of prostaglandins is attributed to; and COX-2, which is induced by cytokines, 
mitogens and endotoxins in inflammatory cells, is implicated to the elevated levels of pros-
taglandins during the inflammation. Prostaglandins are hormone-like mediators involved in 
the induction of pain, fever and inflammation [2]. The inhibition of indomethacin to the two 
COX isozymes with minimal selectivity to COX-2 made the drug have serious complications 
such as gastric ulcers and renal toxicity upon long-term oral administration [4, 5].
Indomethacin and the other NSAIDs were found to have significant anticancer activity against 
wide variety of cancer cell types, in vitro and in vivo [6–10]. Moreover, epidemiological studies 
reported that the use of such type of drugs is linked to the reduction of cancer risk [11–13]. 
Indomethacin performs its anticancer activity in different fashions, inhibits proliferation via 
induction of apoptic death of tumor cells [6, 9, 10], reduces tumorigenesis by enhancing the 
immune response [14, 15] and inhibiting the angiogenesis [16, 17] as well.
Interestingly, to mention that the mechanism to which the anticancer activity of NSAIDs 
including indomethacin attributed is the reduction of PGE2; a type of prostaglandins gener-
ated from the bis-oxygenation of arachidonic acid by COX-2. PGE2 contributes to the cell 
proliferation, cell cycle proliferation and cell cycle progression through various cell signaling 
mechanisms leads to induction of oncogenic genes and eventually overexpression of pro-
liferative proteins [18–22]. Recently, extensive studies on various cancer cell types includ-
ing colorectal carcinoma (CRC) justified the efficacy of indomethacin to reduce the levels of 
antiapoptotic proteins and progressive cell proliferation represented by tumor size by COX-
independent mechanisms [23–26].
After emerge and marketing of celecoxib; selective COX-2 inhibitor in December 1998, rofo-
coxib was released in 1999 worldwide then lumiracoxib and etoricoxib (Figure 1) that are 
marketed in Europe. Those inhibitors are still marketed for the treatment of inflammatory 
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disorders except for rofecoxib and lumiracoxib (the only carboxylic coxib) that were withdrawn 
due to observation of cardiovascular complications from the recommended daily dose with 
rofecoxib [27] and observation of liver failure with lumiracoxib [28]. Selective COX-2 inhibitors 
were launched to treat the individuals who cannot tolerate severe gastrointestinal responses of 
NSAIDs. A few years later, extensive preclinical and clinical data generated to report the role of 
COX-2 in tumor growth and/or metastasis [29]. Studies on experimental animals showed that 
selective COX-2 inhibitors including celecoxib block the formation, growth and metastases of 
multiple tumor types [30]. Consistently, celecoxib demonstrated dramatic chemopreventive 
efficacy against colon polyps and reduced the incidence of recurrent adenomas of any type by 
45% and of high risk lesions by 66% over a 400 mg dose twice daily for 3 years [31, 32]. One of 
the complications that should be tackled in the near future for selective COX-2 inhibitors cele-
coxib in specific is the cardiovascular complications that comes after administration of 400 mg 
twice daily to be the same as the dose recommended for chemopreventive effect to control the 
recurrence of CRC [32, 33]. The magnitude of cardiovascular complications of celecoxib limits 
its use for colon cancer prevention since the development of colon cancer is a slow process, 
so, the patients with polyps would need to take celecoxib for a long period of time to achieve 
the target protective effect. Accordingly, a question should be admitted, and should have an 
evidenced answer: Does the cardiovascular problems of selective COX-2 inhibitors class of 
anti-inflammatory agent come out of pharmacological class effect or chemical class effect? To 
my knowledge, we cannot confirm that it is pharmacological class effect and not chemical class 
effect because the chemical structure of COX-2 inhibitors that share the CVS side effects are 
Y-shaped diaryl-heterocycle sulfonamide/methylsulfonyl. Thus, it is required to develop new 
chemical class of selective COX-2 inhibitors help us be provided with verified answer to such 
important question. The answer of the question would raise the concern to the main reason(s) 
of CVS complications to tackle and eventually modify the strategy toward generation of selec-
tive COX-2 inhibitors with chemopreventive benefits against CRC and other cancer cell types.
Based on the above findings indomethacin, as nonselective COX-inhibitor could be con-
sidered strategic lead compound that worth it studying and developing to line it among 
the chemotherapeutic agents used against cancer to be either prophylactic or therapeutic 
treatment and/or even adjuvant therapy upon combination with other anticancer agents to 
Figure 1. Diarylsulfonamide/methylsulfone selective COX-2 inhibitors.
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synergize the chemotherapeutic effect [25]. The subjected insight in this book chapter regard-
ing indomethacin could be easily justified on scientific bases: (1) indomethacin is the most 
NSAID that is intensively studied as chemopreventive and chemotherapeutic agent against 
multiple cancer cell types among the other drugs of the same class to show observable results. 
(2) Indomethacin as a different chemical class when compared to selective COX-2 inhibitors, 
developing indomethacin-based selective COX-2 inhibitor to excel celecoxib would benefit in 
asserting whether the cardiovascular system (CVS) problems are originated from chemical 
class effect. In case, the reason of the cardiovascular system (CVS) complications is attributed 
to the chemical class effect and indomethacin-based developed structures are devoid of the 
complications, the patients would be largely benefited from such class of compounds, and 
it would be chemopreventive agents used for long time without developing cardiovascular 
system (CVS) complications. (3) Kinetic profile of indomethacin inhibition to COX-2 shows 
recovery after long time of tight binding to the enzyme [34], and on the other hand, selective 
COX-2 inhibitors’ kinetic profile shows no recovery even after long time of tight binding [35]. 
This obvious difference between indomethacin and selective COX-2 inhibitors in performing 
the functionally irreversible inhibition effect to COX-2 has to lead us highlighting indometha-
cin as promising base to build upon it the developed structures in a way to generate selective 
COX-2 inhibitors with minimized serious side effects observed with the diaryl heterocycle 
sulfonamide/methylsulfone class of compounds.
The book chapter covers progressively and in detail some critical topics served in concluding 
future trends in regard to developing indomethacin to be effective chemopreventive and treat-
ment of various cancer cell types without induction of severe cardiovascular system (CVS) 
complications: the implication of COX-2/PGE2 in the anticancer activity of COX-inhibitors, COX-
2-independent mechanisms of anticancer activity of indomethacin, and significance of indomethacin’s 
anticancer activity over the other NSAIDs and selective COX-2 inhibitors.
2. Implication of COX-2/PGE2 in anticancer activity of 
COX-inhibitors
PGE2 implicated in promoting cell proliferation of human esophageal squamous cell carci-
noma. The study started with observation of expression and upregulation of c-Myc, an onco-
genic transcription factor, and then a link was expected to exist between PGE2 and c-Myc but 
requires a reliable elucidation. Deeper studies revealed that PGE2 substantially increased the 
proliferation of cultured esophageal squamous cell carcinoma cells and increased mRNA and 
protein expression of c-Myc. Moreover, knockdown of c-Myc by RNA interference significantly 
attenuated PGE2-induced cell proliferation. Furthermore, a mechanistic study described that 
stability and nuclear accumulation of c-Myc oncogenic protein is attributed PGE2 via phos-
phorylation on serine 62 that induced by extracellular signal regulated kinase (ERK)-dependent 
manner and this was confirmed when PGE2 activation of ERK was fully abolished by protein 
kinase C (PKC) inhibitors. Consistently, PGE2 receptor (EP2) agonist resulted in the same effect 
on expression of c-Myc as PGE2 and knockdown of EP2 receptor by EP2 small interfering RNA 
(siRNA) delayed PGE2-induced c-Myc expression to verify the association of PGE2 to c-Myc 
protein expression in esophageal squamous cancer cell proliferation [18].
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It was reported for celecoxib to be effective after Helicobacter Pylori eradication therapy in 
improving gastric precancerous lesions and stops progression into cancer. The therapeutic 
effect of celecoxib is explained in the study by measuring the expression and activity of COX-2 
for patients with gastric precancerous lesions received celecoxib up to 3 months to be compared 
with those received placebo for the same period of time. The measurements were determined 
by immunostaining and PGE2 assay, cell proliferation by Ki-67 immunostaining, apoptosis by 
TUNEL staining and angiogenesis by microvascular disease (MVD) assay using CD31 stain-
ing. The results showed that there was a significant elevation in COX-2 protein expression in 
gastric precancerous lesions when compared with that resulted from chronic gastritis with 
consequent increase in cell proliferation and angiogenesis. Patients who were treated with 
celecoxib showed significant improvement in gastric precancerous lesions (sites of dysplasia) 
with 84.6% regressed dysplasia, while those treated with placebo showed 60% suggesting that 
celecoxib was effective on the regression of dysplasia. On the other hand, celecoxib effectively 
suppressed cell proliferation, induced cell apoptosis and inhibited angiogenesis exhibited by 
decreased MVD. Interestingly, COX-2 inhibition was accompanied by up-regulation of PPARγ 
expression that is protective protein with reported antineoplastic effects [36].
Overexpression of COX-2 frequently occurred in head and neck squamous cell carcinoma 
(HNSCC). COX-2 promotes the release of pro-inflammatory mediator PGE2 which binds to cell 
surface G-protein coupled receptors EP1–4 to exert its pharmacological effects. Upon study-
ing the biochemical functions of PGE2 and its cell receptors in HNSCC cellular proliferation, 
it was found that COX-2 and cell receptors EP1, EP2 and EP3 were constitutively expressed in 
tumoral lesions of HNSCC. An important finding was declared in the study states that small 
concentration of selective COX-2 inhibitors succeed to suppress PGE2 without inhibition of 
cell proliferation. However, exogenous addition of EP3-specific agonists with PGE2 induces 
DNA synthesis in all HNSCC cell lines. Thus, it could be suggested that EP3 receptor subtype 
of PGE2 should be regarded for future strategies targeting HNSCC prevention [19].
Another study defined a critical mechanism to justify the role of PGE2 in promoting CRC 
cell division in which prometastatic adaptor protein human enhancer filamentation 1 (HEF1) 
links between PGE2 and cell cycle machinery in CRC cells. PGE2 induces expression of HEF1 
mRNA and protein in CRC. Knockdown of HEF1 suppresses PGE2-induced cell proliferation 
and cell cycle progression. CRC cells were examined and found that there is 50% elevated 
levels of HEF1 when compared to normal tissues. Further, HEF1 promotes cell cycle pro-
gression of colorectal carcinogenesis via interaction with and activation of cell cycle kinase 
Aurora A to report that PGE2 is inducer to crucial downstream mediator, HEF1 in colorectal 
carcinogenesis [20].
Small noncoding RNA, microRNAs (miRNAs) have a key role in stopping the translation and 
accelerate the degradation of mRNA that regulates the cellular growth and survival through 
gene suppression. miRNA has a significant contribution in controlling disease progression 
in pancreatic cancer cells (PaCa). Elevated levels of COX-2 were observed with PGE2 and 
decrease in miRNA increased the cancer growth and metastases of PaCa. Restoration of 
miRNA-143 (miR-143) in human PaCa cells reduced COX-2 and inhibited cell proliferation. 
Mitogen activated kinase (MAPC) was correlated to not detecting miR-143 in some pancre-
atic cancer cell subtypes to justify the implication of MAPC activation in regulating miR-143 
beside COX-2 and PGE2 [21].
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α7 Nicotinic acetylcholine receptor (nAChR) protein is significantly biosynthesized via cho-
linergic signaling in nonsmall cell lung cancer (NSCLC) beside COX-2-driven PGE2. The 
mechanism by which PGE2 promoted NSCLC cell proliferation over α-7 nAChR induction 
showed the positive effect of PGE2 on α7 nAChR expression, promotor activity and cell sig-
naling pathways. The association of the two stimulatory factors to cell growth of NSCLC cells 
was confirmed upon attenuation of PGE2-induced cell proliferation via α7 nAChR siRNA or 
acetylcholine transferase. Moreover, PGE2 induced α7 nAChR production was blocked by 
EP4 receptor antagonist and EP4 siRNA. Furthermore, it was recorded that blocking c-Jun, 
critical transcription factor, activated by c-Jun N-terminal kinase (JNK), phosphoinositol 
3-kinase (PI3K) and protein kinase A (PKA), led to abolishing the PGE2-induced α7 nAChR 
production and consequent cell growth. It is worthy to mention that activation of JNK, PI3K 
and PKA resulted from acting of PGE2 on EP4 receptor subtype [22].
Chemopreventive effects of indomethacin was observed for 4-hydroxybutyl(butyl)
nitrosamine(OH-BBN)-induced urinary bladder cancers in mice. The study came over con-
ducting three experiments in which the indomethacin was continually administered prior to 
week 1 or following week 13 OH-BBN dosing for 32 weeks, 1 week after intake of OH-BBN 
at week 13 for 12 weeks and 30 weeks, and 1 week after intake of OH-BBN at week 13 for 
61 weeks, respectively. The chemopreventive effect of indomethacin was observably impres-
sive to show development of palpable bladder masses 3% of animals in case of experiment 
1, 77% decrease in palpable masses and 82% decrease in palpable and microscopic masses in 
case of experiment 2, 26% developed palpable mass under treatment of indomethacin and 
66% in control group in case of experiment 3 [26].
3. COX-2-independent mechanisms of anticancer activity of 
indomethacin
Apoptosis is a programmed cell death induced intrinsically by mitochondrial-mediated or 
extrinsically by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated 
signals [37]. Caspase activation is generally accompanied by apoptosis that is dependent on 
mitochondrial mediated or classical extrinsic TRAIL- or death receptor (DR)-mediated signal-
ing [25]. Tse et al. reported the capability of indomethacin to make tumor cells responsive 
to TRAIL-mediated apoptosis signals through upregulation of TRAIL receptor (DR 5) and 
down-modulation of survivin, antiapoptic protein [38]. The report provided convincing 
mechanism to the indomethacin-induced process to overcome TRAIL-resistant melanomas. 
It is well known that indomethacin enhances mitochondrial oxidative stress and the produc-
tion of reactive oxygen species (ROS) that modulate mitochondrial-mediated signaling [39]. 
ROS induces the transcription factor, C/enhancer-binding homologous protein that leads to 
upregulation of DR 5 on tumor cells. Moreover, ROS has a role in down-modulation of sur-
viving via inhibition of transcription of the known regulator, NF-kB [37]. The report suggests 
that indomethacin could successfully sensitize TRAIL-resistant melanoma cells.
The ability of indomethacin to work against HCT116 human CRC cells does not express COX 
was reported using proteomic approach to identify the mechanism by which indomethacin 
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inhibit the CRC growth. The total proteins from indomethacin-treated and untreated cancer 
cells were separated by immobilized pH gradient-based two-dimensional gel electrophoresis. 
The different proteins produced throughout the test were identified by peptide mass finger-
print (PMF) based on matrix-assisted laser desorption/ionization time of flight mass spec-
trometry. The results revealed that indomethacin induced HCT116 apoptosis and inhibited 
cell growth by downregulation Wnt1-inducible signaling pathway protein 1, Bcl-2-related 
protein A1 and mitogen-activated protein kinase [24].
c-AMP activates PKA in and c-AMP-response element binding (CREB) protein in melano-
genesis. CREB plays an important role in binding to the promotor of the microphthalmia-
associated transcription factor (Mitf) gene and consequently activates Mitf gene transcription 
[40, 41]. Thus, Mitf has a crucial role in transcription of melanogenic genes and activates mela-
nogenic gene transcription of tyrosinase as well. Indomethacin was studied to investigate 
the effect on melanogenesis in B16F1 melanoma cells. The study resulted in indomethacin 
inhibited α-melanocyte stimulating hormone that enhances melanin synthesis in melanoma 
cells., suppressed tyrosinase and Mitf protein levels, reduced tyrosinase promoter activity, 
lowered mRNA of melanogenic genes, including Mitf gene [23].
AMP-protein kinase (AMPK) is a key factor of master regulation of cellular energy homeo-
stasis [42]. When AMPK is activated, it induces block of cell cycle and apoptotic cell death 
in different types of cancer cells including gliomas, the primary tumors of central nervous 
system [43–47]. The apoptotic death and inhibition of growth of cancer cell actions of AMPK 
are mediated by one of the signaling pathway in which mammalian target of rapamycin 
(mTOR) is inhibited. It is worthy to note that mTOR is a catalytic core for formation of two 
definite complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2) and both are sensitive 
targets to rapamycin, allosteric inhibitor of the complexes [48]. mTORC1 has a supporting 
role in protein synthesis and cell proliferation. mTOR performs its biological functions by 
phosphorylating ribosomal p70S6 kinase and translational repressor 4E-BP1 [48]. AMPK 
phosphorylates raptor and/or tuberous sclerosis complex-mediated inhibition of mTOR 
stimulator Ras homolog enriched in brain (RHEB) [49]. Beside the role of mTORC1 in cell 
proliferation, it causes major and observable negative regulation to intracellular degradation 
of unnecessary and dysfunctional cellular components through lysosomal machinery which 
is a kind of cytotoxic mechanism [50]. Indomethacin was reported as growth inhibitor to 
CRC cells by mTOR inhibition [51]. For the glioma cells U251, indomethacin showed supe-
rior in vitro antiglioma action and restriction to cell proliferation to the other COX-inhibitors 
when tested against the same cancer cells. The antiproliferative and proapoptotic actions 
of indomethacin against U251 was evidenced by G2M cell cycle arrest P21 associated with 
caspase-3/9 activation, DNA fragmentation that were displayed by indomethacin-treated 
glioma cells [52]. Also, indomethacin stimulates AMPK phosphorylation in glioma cells 
and the implication of this pathway in antiglioma effect of indomethacin was confirmed 
by knockdown of AMPK via RNA interference to alter the AMPK activity and antiglioma 
actions of indomethacin. Generally, AMPK seemed not sufficient antiproliferative pathway 
to restrict glioma cell proliferation. Therefore, it is expected that treating glioma cells with 
indomethacin had a synergistic effect came from its AMPK-dependent and -independent 
pathways in inhibiting the cancer cell growth and proliferation of gliomas.
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4. Significance of indomethacin and its developed structures’ 
anticancer activity over the other NSAIDs and selective COX-2 
inhibitors
According to the literature scan had been done on indomethacin as nonselective COX-inhibitor 
and antiproliferative agent, it could be observed that indomethacin is the most NSAID that 
attracted the interest of researchers to study, investigate, identify more about the definite 
mechanisms and cellular signaling pathways involved in the antiproliferative and apoptotic 
effects of indomethacin. This might be attributed to two apparent points: one is the observable 
inhibition of cell growth, reduction of tumor size and implication in the programmed cell death 
of multiple tumor cell types including glioma and glioblastomas that require lipophilicity for 
cell penetration. The second is that indomethacin exhibited its anticancer activity against wide 
variety of cancer cell types by COX-2/PGE2-dependent and -independent mechanisms. This 
adds great advantage to indomethacin over the other nonselective COX-inhibitors because in 
that way, indomethacin has dual actions by which it could exert its cytotoxic activity effectively.
Regarding the selective COX-2 inhibitors, the prophylactic actions of celecoxib against recur-
rence of colon polyps is defined by researchers as dramatic to indicate the capability of cele-
coxib and other COX-2 inhibitors to block the cancer cell growth and metastases as well. 
One serious complication that is developed upon long-term therapy of celecoxib that limits 
its use as chemopreventive therapy for CRC is the cardiovascular toxicity that results from 
critical reduction in PGE2 and prostacyclin (PGI2) production. Those types of prostaglandins 
are COX2-dependent product responsible for regulating vascular tone and atherosclerosis 
[53]. The problem is absolutely the same as all the selective COX-2 inhibitors since they share 
the same pharmacological action in which production of prostaglandins is significantly 
diminished.
Some differential points related to the kinetic profile of both indomethacin [34] and selective 
COX-2 inhibitors [35] were worth it stopping at to help us draw a future plan to develop 
indomethacin’s chemical structure in a way to enhance COX-2 inhibition activity like selective 
COX-2 inhibitors and be devoid of cardiovascular complications as well. Nonselective inhibi-
tors including indomethacin perform its inhibition action against the enzyme through 2-step 
inhibition mechanism involving slow and time-dependent step due to tight reversible bind-
ing to the enzyme to be considered as functionally irreversible. But selective COX-2 inhibitors 
inhibit the enzyme through 3-step inhibition mechanism involving time-dependent step that 
represents the tightly bound complex of inhibited enzyme. The observation that should be 
highlighted for both types of COX-inhibitors while monitoring the kinetic model of inhibition 
mechanism is that indomethacin carboxylic acid is not essential for the tight binding and 
time-dependent step of enzyme inhibition because the esterified counterpart did not abolish 
this step or even reduce the tightness of binding to human COX-2 and the formation of the 
complex maintained functionally irreversible [54, 55]. Further, indomethacin recovered intact 
after prolonged time of incubation with the enzyme, this suggests that enzyme inhibition 
came over conformational change not covalent bond formation [34]. On the other hand, DuP 
697, selective COX-2 inhibitor showed the same time-dependent step that was responsible for 
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drug’s selective inhibition of human COX-2 but impressively the inhibitor did not show suc-
cessful recovery even upon dialysis but the inhibitor is freed to inhibit another enzyme under 
the effect of denaturation to confirm that the tight binding of inhibitor to the enzyme was not 
based on formation of covalent bond [35].
The detrimental differences in regard to the kinetic profile of indomethacin, nonselective 
COX-inhibitor and DuP 697, selective COX-2 inhibitor for inhibition of COX-2 raised my con-
cern with that emerge of developed selective COX-2 inhibitors based on indomethacin would 
definitely help us answer two important questions:
i. Is the cardiovascular toxicity of selective COX-2 inhibitors pharmacological class effect of chemical 
class effect? The change of chemical class of selective COX-2 inhibitors from the traditional 
diaryl heterocycle sulfonamide/methylsulfone to indomethacin-based structures and 
identifying the kinetic profile of the new class of selective inhibitors would provide a 
strong evidence on the real reasons of cardiovascular problems after administration of 
selective COX-2 inhibitors to discover whether it lies behind the kinetic mode of enzyme 
inhibition which depends on the chemical structure or it lies behind the selective action 
of the drug against COX-2. In case of similar kinetic profile for the generated new inhibi-
tors to the traditional class and no recovery to the inhibitor is shown, so, it will imply 
that it is a general feature to the selective inhibitors whatever is the chemical structure. 
It could be drawn that the inability of selective inhibitors to get recovered from COX-2 
enzyme might be a significant reason to the CVS complications of the inhibitors. In case, 
the new structures saved the kinetic profile of the original lead compound, indomethacin, 
so, it would be worth it monitoring the development of CVS problems after long-term 
administration of the newly developed indomethacin-based compounds. There are two 
reports based on epidemiological studies stated clearly that prolonged use of NSAIDs is 
associated by small increase in CVS risk [56, 57]. This attracted our attention to comment 
on that this happens though NSAIDs inhibit COX-2 with the same efficacy as selective 
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COX-2 inhibitors. Thus, it is suggested that chemical structure and/or binding mode most 
likely play a significant role in determining the kinetic mode of enzyme inhibition. But, 
we are still in serious need to an evidence results from experimental studies to assertively 
answer the above question.
ii. Would the anticancer activity of indomethacin be enhanced with the new indomethacin-based 
compounds? Improvement of the selective inhibition of COX-2 in comparison to indo-
methacin is supposed to potentiate the antiproliferative and apoptotic activities upon 
enhanced diminishing to COX-2/PGE2, combining this important signaling pathway with 
the COX-2-independent mechanisms of anticancer activities that previously described in 
this book chapter for indomethacin in Section 2 “COX-2-independent mechanisms of 
anticancer activity of indomethacin”.
Several attempts for generation of indomethacin-based analogs of selective COX-2 inhibition 
activity [58–60], but the publication that I had to put it in focus in this regard is that described 
the design and synthesis of indomethacin-based analogs of potentially selective COX-2 inhibi-
tion activity and observed diminishing to PGE2 [61]. The successful generation of developed 
indomethacin structures with selective COX-2 inhibition activity was iteratively reported in 
the literature but picking this publication to comment on among the others was based on the 
obvious selectivity index of the generated analogs that excelled celecoxib, dramatic lowering 
to plasma levels of PGE2 when compared to indomethacin, the innovative perspective upon 
Figure 2. Biological data of the new indomethacin-based selective COX-2 inhibitors 1 and 2 in comparison with 
indomethacin and celecoxib.
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which the design and modification of the analogs are designed, and above all of this the bio-
logical profiling through multiple in vitro and in vivo tests that done for the analogs to impress 
the discovery of interesting tetrahydrocarbazole candidates. Accordingly, the newly selective 
COX-2 inhibitors worth it promoting to study how far it is implicated in CVS toxicity upon 
long-term therapy against either cancer or inflammatory diseases.
The new tetrahydrocarbazole selective COX-2 inhibitors (1) and (2) (Figure 2) generated 
were based on enlarging the size of indomethacin indole ring to occupy the wider cata-
lytic pocket of COX-2 than COX-2 by 25% [62] and reducing the opportunity of the ring-
extended candidates to interact with COX-1 to raise the selectivity. Introduction of methyl 
sulfonyl group to replace methoxy group of indomethacin at position 6 to enhance the 
interaction of the designed inhibitor (2) (Figure 3) with the polar side pocket of COX-2 
(selective pocket) that is critical for COX-2 inhibition activity [63]. Deletion of carboxylic 
acid from the new candidates (1) and (2) reduce the possibility of the inhibitor to interact 
with COX-1 via formation of salt bridge with Arg120 amino acid (Figure 3) [64] that is criti-
cal for conformational change and inhibition of the isoenzyme. Impressively, the biological 
results throughout in vitro testing represented by enzymatic assays against human COX-1 
(hCOX-1) and hCOX-2 and in vivo testing represented by % inhibition of plasma PGE2 
and others revealed the successful verification of the proposed hypothesis suggested to 
enhance the COX-2 inhibition selectivity. Methoxy derivative (1) (Figure 2) gave selectivity 
index against COX-2 (207.2165) to excel both that of indomethacin (0.98859) and celecoxib 
(333.3333) standard drugs. For the methylsulfone derivative (2) (Figure 2), it excelled the 
standard materials at much higher value (452.1739). Moreover, the diminishing of plasma 
levels of PGE2 was very observable in comparison to indomethacin (98.29%) and celecoxib 
(77.25%) (Figure 2). Thus, kinetic profile of the enzyme inhibition of the new candidate (2) 
in the near future would answer the questions described in this section on the book and 
eventually be able to judge on the chemopreventive of the new selective COX-2 inhibitor 
and antiproliferative activity as well.
Figure 3. Schematic representation of SC-558 (COX-2 selective inhibitor) binding to COX-2 (a) and indomethacin 
(nonselective inhibitor) (b).
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5. Conclusions
Generation of indomethacin-based analogs to indomethacin aiming at enhancing the selective 
COX-2 inhibition would definitely help us answer an important question concerning the real 
reason of cardiovascular toxicity of selective COX-2 inhibitors, whether it is pharmacologi-
cal class effect or chemical class effect. Moreover, enhancing the selectivity of indomethacin 
against COX-2 among the other NSAIDs providing a candidate privileged with potential anti-
inflammatory activity devoid of gastrointestinal side effects and what is more important is 
obtaining newly developed structure carries effective antiproliferative and apoptotic activity 
standing for the dual actions reported for indomethacin as a lead compound based on that it 
performs its anticancer activity by both COX-2-dependent and COX-2-independent mecha-
nisms. Further, the CVS toxicity is expected to be minimized upon enhancing the selective 
COX-2 inhibition of indomethacin due to observation that there might be a difference in the 
kinetic mode of enzyme inhibition between diaryl heterocycle sulfonamide/methylsulfone 
chemical class of selective COX-2 inhibitors and the new indomethacin-based chemical class 
of compounds that may permit successful recovery of the new inhibitors from the enzyme 
after long incubation period.
Nomenclature
NSAID nonsteroidal anti-inflammatory drug
COX cyclooxygenase
PG prostaglandin
CRC colorectal carcinoma
CVS cardiovascular
ERK extracellular signal regulated kinase
PKC protein kinase C
siRNA small interfering RNA
MVD microvascular d
HNSCC head and neck small cell carcinoma
HEF1 human enhancer filamentation 1
miRNA microRNA
MAPC mitogen activated kinase
NSCLC nonsmall cell lung cancer
JNK c-Jun N-terminal kinase
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PI3K phosphoinositol 3-kinase
PKA protein kinase A
OH-BBN 4-hydroxybutyl(butyl)nitrosamine
TRAIL tumor necrosis factor-related apoptosis-inducing ligand
DR death receptor
ROS reactive oxygen species
PMF protein mass fingerprint
CREB c-AMP-response element binding
AMPK adenosine monophosphate kinase
mTOR mammalian target of rapamycin
RHEB Ras homolog enriched in brain
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